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Tacrolimus (FK-506) is a part of most immunosuppressive protocols after kidney 
transplantation because it significantly affects the survival of transplanted organs in post 
- transplantation period. FK-506 is characterized by a narrow therapeutic index and 
large interindividual variability in pharmacokinetics. Partly, these variations can be 
explained by 6986A>G polymorphism CYP3A5 gene. As a substrate for CYP3A5 
isoenzyme, FK–506 has a different elimination rate amnog  individuals, which is caused 
by CYP3A5 gene polymorphism.  
   The primary objective of this study was to investigate the frequency of CYP3A5 
gene polymorphism (6986A>G) in kidney transplant patients and comparison with the 
healthy volunteers. The second objective of this study was to determine the influence of 
the investigated polymorphism on FK–506 dosage regimen one month after kidney 
transplantation. 
Pharmacogenetic retrospective study included 121 examinees - 60 patients with 
renal transplant and 60 healthy volunteers. Patients have routine determination of drug 
concentration at the Clinic of Nephrology, Clinical Center Niš, Serbia. PCR method 
(Ashavaid TF et al.)  was used to determine the polymorphism of CYP3A5 gene. 
   Our study did not show statistically significant differences in allele (p=0.616) and 
genotype (p=0.602) frequencies between the studied polymorphism in renal transplant 
patients and healthy volunteers. A statistically significant difference was found between 
patients with different genotypes of CYP3A5 regarding dose (p=0.001), weight adjusted 
dose (p=0.005), and dose normalized level of FK–506 (p=0.039) one month after 
transplantation. 
    Patients with kidney transplant and healthy subjects in Serbian population did 
not show difference in the frequency of alleles of CYP3A5 gene. CYP3A5 gene 
polymorphism affects the dose regimen of tacrolimus one month after kidney 
transplantation. Acta Medica Medianae 2013;52(1):33-38. 
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Introduction 
 
Tacrolimus (FK-506) is a part of most immuno-
suppressive protocols after kidney transplantation. 
It significantly affects the survival of transplanted 
organs in post-transplantation period, but also it 
can cause adverse effects and toxicity. Due to 
the narrow therapeutic index and large inter-
individual variability in pharmacokinetics, therapeutic 
drug monitoring is required in order to reduce the 
toxicity and improve efficiency. Consequences of 
both, under-immunosuppression or over-immuno-
suppression can be potentially severe. Under-
immunosuppression increases the risk of immune-
mediated rejection of transplanted organs, which 
leads to potential organ loss. Otherwise, over-
immunosuppression increases the risk of serious 
infections and malignancies, as well as a number 
of complications such as nephrotoxicity and post-
transplantation diabetes mellitus (1-3). Cytochrome 
P450 3A4 (CYP3A4) and cytochrome P450 3A5 
(CYP3A5) are the major enzymes in the 
metabolism of FK–506. Functional CYP3A4 is 
located in the liver and small intestine of each 
individual. Conversely, functionally active CYP3A5 
only exists in some individuals (expressers). 
Otherwise, CYP3A5 is expressed in the liver, 
small intestine and kidney. Expresser has one of 
the wild-type alleles (CYP3A5*1) and may carry 
one of the two possible genotypes, CYP3A5*1/*1 
or *1/*3. Non–expressers are homozygous for 
mutant allel, CYP3A5*3/*3. Differences among 
individuals are resulted in 6986A>G polymorphism 
of CYP3A5 gene, which leads to a failure in the 
synthesis of functional enzyme. Earlier studies 
have shown that CYP3A5 6986A>G polymorphism 
influences the pharmaco-kinetics of FK-506 (4-7). 
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has a different elimination rate among individuals 
with different pair of alleles. Almost all studies 
have confirmed that carriers of CYP3A5*3/*3 
genotype require lower doses than carriers of 
CYP3A5*1/*1 or *1/*3 genotype to maintain drug 
level in optimal range (8-10). As the CYP3A5 is 
expressed within the kidneys, the primary objective 
of this study was to investigate the frequency of 
CYP3A5 gene polymorphism (6986A>G) in kidney 
transplant patients and comparison with the 
healthy volunteers. The second objective of this 
study was to determine the influence of the 
investigated polymorphism on FK–506 dosage 
regimen one month after kidney transplantation. 
 
Patients and methods 
 
Patients 
 
Pharmacogenetic retrospective study included 
121 examinees (61 patients with renal transplant 
and 60 healthy volunteers). Patients have routine 
determination of drug concentration at the Clinic 
of Nephrology, Clinical Center Niš, Serbia. All 
patients included in this study were on quater-
nary immunosuppressive protocol which is based 
on FK-506. FK-506 was introduced on the 5
th day 
after transplantation with initial drug dose of 0.05 
mg/kg/day. After the first dose, FK-506 was 
administered twice daily (08:00 h and 20:00 h), 
and the dose was adjusted according to the level 
of drug in the blood, in order to maintain drug 
level in the appropriate range (5-15 ng/ml). 
Besides FK-506, the patients received corticosteroid 
- methylprednisolone in the initial dose of 0.5 
g/day, i.v., after were switched to prednisone, 
mycophenolate mofetil with an initial dose of 1.5 
g/day and a monoclonal antibody, basiliximab in 
a dose of 20 mg on the 1s
t and 4
th day after 
transplantation. Concentration of FK-506 in the 
blood was measured by immunoassay method 
according to the manufacturer's instructions (IMX, 
Abbott, Abbott Park, IL, USA). 
 
Method for CYP3A5 gene polymorphism 
detection 
 
In order to determine polymorphism in the 
CYP3A5 gene, we had to isolate DNA from the 
patients and controls. DNA was isolated from the 
whole blood with EDTA as an anticoagulant using 
Genomic DNA Purification Kit (Fermentas, Thermo 
Scientific, Lithuania) according to the manu-
facturer's instructions. Ashavaid TF et al., PCR 
method was used to determine the polymorphism 
of CYP 3A5 gene (11). Each reaction mixture in a 
total volume of 25 µL, contained 12.5 µL of 
KAPA2G Readymix (KAPA2G Readymix FastHot-
Start, KapaBiosystems, Boston, USA), which 
already contained Hot Start DNA polymerase, 
dNTPs, MgCl2 and stabilizers. In addition to the  
commercial mix, we added 0.5 µL of both primers 
(forward and reverse, concentration of 10 pmol/µL), 
10.5 µL of deionized water and 1 µL of isolated 
DNA (average concentration 50 ng/µL). For the 
amplification of PCR products, we followed the 
program: initial  denaturation for 2 min at 95oC, 
followed with 35 cycles of denaturation for 15 sec 
at 95°C, annealing for 15 sec at 60°C, elongation 
for 15 sec at 72°C with final elongation for 30 sec 
at 72°C. Amplification products were detected on 
3% agarose gel. 
 
Statistical Data 
 
Tables of contingency were analyzed using 
the Chi-square (χ
2) or Fisher test when the 
expected frequency was less than 5%. χ
2-test was 
used to test a statistically significant difference in 
the frequency of alleles and genotypes between 
population of patients and healthy volunteers. 
Allele and genotype frequencies were assessed 
for deviation from Hardy-Weinberg equilibrium 
using the Fisher exact test. Doses, drug levels, 
and dose normalized levels between groups of 
patients with different genotypes were compared 
using T-test if the distribution was normal in the 
two groups. If there was a deviation from the 
normal distribution in the two groups, Mann - 
Whitney U test was performed. The value of P<0.05 
was considered significant. We used Statistical R 
software for statistical calculations. This study 
was approved by the Ethics Committee of the 
Faculty of Medicine. 
 
Results 
 
Demographic characteristics of the patients 
and controls are given in Table 1.  
CYP3A5 genotypes and alleles were in 
Hardy-Weinberg equilibrium. The frequency of 
genotypes and alleles for the CYP3A5 gene in the 
population of patients and healthy subjects are 
shown in Table 2. In patient population, 10 of 61 
patients (16, 39%) were heterozygous (CYP3A5 
*1/*3) for the studied polymorphism, while 51 
(83, 61%) patients were homozygous for the 
mutant type allele (CYP3A5*3/*3). Patients homo-
zygous for the wild-type allele were not present. In 
the control group, 7 of 60 subjects (11.67%) 
were heterozygous, while 53 controls (88.33%) 
were homozygous (CYP3A5*3/*3). Also, we did 
not determine homozygous for the wild-type allele 
in a control population. The frequency of CYP3A5*1 
allele in the patient population was 8.2%, while in 
the population of healthy volunteers it was 5.83%. 
Accordingly, the frequency of CYP3A5*3 allele 
was 91.8% and 94.17%, respectively. There was 
no statistically significant difference in allele 
(χ
2=0.517, p=0.616) and genotype frequencies 
(χ
2=0.560, p=0.602) of CYP3A5 gene between 
patients and controls. Acta Medica Medianae 2013, Vol.52(1)                                             Significance of CYP3A5 gene polymorphism in Serbian renal... 
Table 1. Demographic characteristics of the patients and controls. Age is expressed as mean ± standard deviation 
 
   Kidney transplant patients 
n=61 
Healthy volunteers - controls 
n=60 
Age (years)  39.11 ± 10.13  40.40 ± 11.21 
Gender (male / female)  40/21  33/27 
Type of transplantation (living/ cadaveric)  49/12  / 
 
Table 2. The frequency of CYP3A5 alleles and genotypes in a population of patients and controls. Results are 
expressed as a number of subjects (percentage of subjects) 
 
Table 3. Dose, weight-adjusted dose, level and dose- normalized level (C0/Dose) of FK-506 between patients with 
a different genotype for CYP3A5. Results are expressed as mean ± standard deviation, median (interquartile 
range) 
 
Genotype *1/*3  *3/*3 
Dose of FK-506 
(mg / day) 
11.50 ± 4.06
# 
12.00 (9.50 – 13.00) 
7.39 ± 3.02 
7.50 (5.00 – 9.00) 
Weight adjusted dose of FK-506 
(mg / kg / day) 
0.16 ± 0.04
## 
0.18 (0.14 – 0.18) 
0.11 ± 0.05 
0.09 (0.07 – 0.13) 
Level of FK-506 
(ng / mL) 
9.63 ± 1.89 
10.00 (7.90 – 11.35) 
8.94 ± 2.33 
8.80 (7.00 – 10.90) 
Dose normalized level of FK-506 
(ng mL
-1 / mg kg
-1day
-1) 
65.16 ± 21.98
### 
62.70 (51.88 – 71.98) 
96.32 ± 43.24 
89.76 (61.98 – 111.82) 
  35 
#: *1/*3 vs. *3/*3, p=0.001 
##: *1/*3 vs. *3/*3, p=0.005 
###: *1/*3 vs. *3/*3, p=0.039 
 
Table 3 shows dose (mg/day), weight 
adjusted dose (mg/kg/day), level (ng/mL) and 
dose-normalized level (C0/Dose) of FK-506 (ng 
mL
-1/mg kg
-1day
-1) one month after renal trans-
plantation. The obtained values were compared 
between groups of patients with different geno-
types of CYP3A5. A statistically significant difference 
was found between patients with different geno-
types of CYP3A5 regarding dose (p=0.001), weight-
adjusted dose (p=0.005), and dose-normalized 
level of FK-506 (p=0.039) one month after trans-
plantation. 
 
Discussion 
 
CYP3A5 gene has 11 different poly-
morphisms, which have been identified to date. 
CYP3A5 (6986A>G) polymorphism (rs776746) is 
most extensively studied and it is characterized 
by adenine (A) to guanine (G) transition at 
position 6986 within intron 3 of the CYP3A5 gene. 
Expressers (carriers of CYP3A5*1 allele) produce 
high level of full-length messenger RNA (mRNA), 
which consequently leads to high level of CYP 
3A5 functional protein in the body. The frequency 
of CYP3A5*1 allele is largely dependent on ethnic 
origin (7). In Caucasians, the frequency of CYP3A5*1 
allele is approximately 5-15% (7), which is 
consistent with our results: 8.2% in transplant 
patients and 5.83% in healthy volunteers. Frequency 
of this allele varies among other ethnic groups: in 
African - Americans is between 45-73%, 15% in 
Japanese, 27-35% in Chinese, 30% in Koreans, 
25% in Mexicans and 27% in Moroccans (7-14). 
Hill et al., have shown that the CYP3A5*1 allele is 
represented with 7.9% in the population of Finns 
(15). Among the other Europeans, this percent 
was: the Greeks 5.6%, the British 6%, the Dutch 
8.3% and the French 13% (16-19). The results of 
our study indicate that the frequency of alleles 
and genotypes of CYP3A5 does not differ among 
transplant patients and healthy volunteers, which 
i s  c o n s i s t e n t  w i t h  t h e  r e s e a r c h  o f  L a r r i b a  e t  a l .  
(20). This could imply that studied polymorphism 
does not underlie the kidney disease that 
consequently leads to kidney failure and organ 
transplantation.  
Adequate immunosuppression is necessary 
in early period after transplantation, when there 
is a high risk of acute rejection of the trans-
planted organ. This fact with large interindividual 
differences in pharmacokinetics of FK–506 between 
individuals suggest that therapeutic drug moni-
toring is gaining the major importance (21,22). 
Recent identification of genetic polymorphism in 
genes that encode enzymes involved in drug 
Genotype Allele   
*1/*3 *3/*3 *1  *3 
Patients  10 (16.39%)  51 (83.61%)  10 (8.20%)  112 (91.80%) 
Controls  7 (11.67%)  53 (88.33%)  7 (5.83%)  113 (94.17%) Significance of CYP3A5 gene polymorphism in Serbian renal...                                                                   Nikola Stefanović et al. 
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metabolism implies that genetic factors may 
influence interindividual variability in the pharma-
cokinetics of FK-506. Earlier pharmacogenetic 
studies have shown the impact of CYP3A5 
6986A>G polymorphism on the pharmacokinetics 
of FK-506 (7). Also, studies have shown that 
carriers of CYP3A5*1 allele have a 25-40% higher 
clearance of FK-506, lower drug normalized levels 
as well as higher dose requirement to maintain 
an optimal level of drug, 5-15 ng/mL) (23-27). 
Our results suggest that the dose-and the weight-
adjusted dose were affected by CYP3A5 genetic 
polymorphism (p=0.001 and p=0.005, respectively). 
These results are consistent with the results of 
other authors that emphasize the importance of 
polymorphism of CYP3A5 in the early period after 
transplantation (28-30). Also, we showed that 
carriers of CYP3A5*1 allele require higher doses 
of FK-506 compared to non-expressers. In addition, 
almost all studies have shown that CYP3A5 poly-
morphism affects C0/dose, C2/dose or AUC (area 
under the c-t curve)/dose (7,28,31-34). Our research 
confirmed the results from previous studies. 
Serbian kidney transplant patients with CYP3A5*1 
allele have C0/dose, C2/dose or AUC (area under 
the c-t curve)/dose. 
In conclusion, patients with kidney transplant 
and healthy subjects in Serbian population did 
not show a difference in the frequency of alleles 
of CYP3A5 gene. CYP3A5 gene polymorphism 
affects the dose regimen of tacrolimus one month 
after kidney transplantation. Regarding this results 
we confirmed the importance of CYP3A5 poly-
morphism research in renal transplant patients. 
The following studies should be more involved 
into research of pharmacodynamics–pharmaco-
genetics relationship of tacrolimus as well as other 
drugs. 
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ZNAČAJ POLIMORFIZMA CYP3A5 KOD BOLESNIKA SA 
TRANSPLANTIRANIM BUBREGOM U SRBIJI 
 
Nikola Stefanović, Tatjana Cvetković, Radmila Veličković-Radovanović, 
Tatjana Jevtović- Stoimenov, Dijana Stojanović i Nataša Živković 
 
 
Takrolimus (FK-506) čini sastavni deo većine imunosupresivnih protokola nakon 
transplantacije bubrega, jer značajno utiče na preživljavanje presađenog organa u 
posttransplantacionom periodu. FK-506  karakteriše  uzak terapijski indeks i velika 
interindividualna varijabilnost u farmakokinetici, koja se delimično može objasniti 
polimorfizmom 6986A>G CYP3A5 gena. FK–506 je supstrat za CYP3A5 izoenzim i 
polimorfizam CYP3A5 gena. On uslovljava razlike u brzini eliminacije ovog leka kod 
pojedinaca. 
Primarni cilj istraživanja bio je ispitivanje učestalosti polimorfizma CYP3A5 
(6986A>G) gena kod bolesnika sa transplantiranim bubregom i poređenje sa zdravim 
dobrovoljcima. Drugi cilj istraživanja bio je utvrđivanje uticaja ispitivanog polimorfizma 
na dozni režim takrolimusa mesec dana nakon transplantacije bubrega.  
Retrospektivno farmakogenetičko istraživanje obuhvatilo je 121 ispitanika (61 
bolesnik sa transplantiranim bubregom i 60 zdravih dobrovoljaca). Bolesnicima sa 
transplantiranim bubregom rutinsko određivanje koncentracije leka vršeno je na  Klinici 
za nefrologiju Kliničkog centra Niš, Srbija. PCR metod (Ashavaid TF i sar.) korišćen je 
za određivanje polimorfizma CYP3A5 gena.  
U našem istraživanju nije bilo statistički značajne razlike u pogledu učestalosti 
alela (p=0,616) i genotipova (p=0,602) ispitivanog polimorfizma između bolesnika sa 
transplantiranim bubregom i zdravih dobrovoljaca. Bolesnici sa različitim genotipovima 
za CYP3A5 statistički su se značajno razlikovali u pogledu doze (p=0,001), doze 
korigovane težinom (p=0,005) i nivoa korigovanog dozom (p=0,039) mesec dana 
nakon transplantacije.  
Bolesnici sa transplantiranim bubregom i zdravi ispitanici u srpskoj populaciji 
nisu pokazali razlike u učestalosti alela CYP3A5 gena. Polimorfizam CYP3A5 gena utiče 
na dozni režim takrolimusa mesec dana nakon transplantacije bubrega. Acta Medica 
Medianae 2013;52(1):33-38. 
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